Inovio Pharmaceuticals, Inc.
INO
$1.68
$0.053.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -23.04% | -8.18% | |||
| Gross Profit | 23.04% | 8.18% | |||
| SG&A Expenses | -8.40% | -8.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.60% | -8.12% | |||
| Operating Income | 17.60% | 8.12% | |||
| Income Before Tax | 108.28% | -93.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 108.28% | -93.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.28% | -93.44% | |||
| EBIT | 17.60% | 8.12% | |||
| EBITDA | 17.85% | 8.22% | |||
| EPS Basic | 106.96% | -43.98% | |||
| Normalized Basic EPS | 106.93% | -43.73% | |||
| EPS Diluted | 106.96% | -43.98% | |||
| Normalized Diluted EPS | 106.93% | -43.73% | |||
| Average Basic Shares Outstanding | 18.91% | 34.35% | |||
| Average Diluted Shares Outstanding | 18.91% | 34.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||